As the ACT of T-cells genetically engineered to express tumor-reactive TCRs can elicit regression of widespread cancer in patients with metastatic disease, the TCRs isolated above may extend TCR gene therapy to HLA-C*08:02 patients whose tumor express KRASG12D, including AML patients. The gene discussed is HLA-C; the disease is acute myeloid leukemia.